Literature DB >> 2655094

Optimal dosing with carboplatin.

R F Ozols1.   

Abstract

Carboplatin is a new cisplatin analogue that has a spectrum of activity similar to that of the parent compound. Since the dose intensity of cisplatin is important in achieving optimal results, it is probable that carboplatin dosage is an important factor in maximizing efficacy, particularly in platinum-sensitive tumors. Renal function and prior history of chemotherapy are the most important factors in selecting an individual patient's dose. In ovarian cancer patients, the usual dose of carboplatin will be 300 to 400 mg/m2 and will depend upon whether carboplatin is used as salvage therapy or as part of an induction combination chemotherapy regimen in previously untreated patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655094

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer.

Authors:  R L Basser; M D Green; W P Sheridan; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures.

Authors:  F Doz; M E Berens; D V Dougherty; M L Rosenblum
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.